The purpose of this study is to find the highest dose of an investigational drug called E7080 that can be given in combination with everolimus in patients with advanced or metastatic renal cell carcinoma (a serious form of kidney cancer) that persists despite prior treatment with a drug that targets the VEGF receptor. Both E7080 and everolimus are taken orally (by mouth).
E7080 is thought to work by stopping the formation of new blood vessels that help cancer cells grow and spread. Everolimus is already approved for treating renal cell carcinoma. It works by inhibiting a protein called mTOR, which is involved in tumor cell growth and the growth of blood vessels that help cancer cells grow and spread.